Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Leukemia

Free Subscription 18.02.2019 1 Am J Clin Oncol 3 Ann Hematol 1 Blood 1 BMC Cancer 11 Br J Haematol 1 Cell 3 Eur J Haematol 1 Exp Cell Res 2 Exp Hematol 1 Gene 1 Int J Hematol 1 J Clin Oncol 2 J Natl Cancer Inst 1 Leuk Lymphoma 2 Leukemia 1 Oncogene 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Clin Oncol

1. JABBOUR E, Makenbaeva D, Lingohr-Smith M, Lin J, et al
   Impact of Genetic Mutations and Health Plan Access to Therapies on Treatment Response and Drug Costs Related to Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myelogenous Leukemia.
   Am J Clin Oncol. 2018;41:213-217.
   PubMed     Text format     Abstract available
   
   

   
   Ann Hematol

2. XIE W, Hu S, Xu J, Chen Z, et al
   Acute myeloid leukemia with t(8;16)(p11.2;p13.3)/KAT6A-CREBBP in adults.
   Ann Hematol. 2019 Feb 13. pii: 10.1007/s00277-019-03637.
   PubMed     Text format     Abstract available
   
   
3. GAO XN, Lin J, Wang LJ, Li F, et al
   Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia.
   Ann Hematol. 2019 Feb 12. pii: 10.1007/s00277-019-03636.
   PubMed     Text format     Abstract available
   
   
4. KUNZ F, Kontopoulou E, Reinhardt K, Soldierer M, et al
   Detection of AML-specific mutations in pediatric patient plasma using extracellular vesicle-derived RNA.
   Ann Hematol. 2019;98:595-603.
   PubMed     Text format     Abstract available
   
   

   
   Blood

5. MCRAE HM, Garnham AL, Hu Y, Witkowski MT, et al
   PHF6 regulates hematopoietic stem and progenitor cells and its loss synergizes with expression of TLX3 to cause leukemia.
   Blood. 2019 Feb 12. pii: blood-2018-07-860726. doi: 10.1182/blood-2018-07-860726
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

6. DUMAS PY, Mansier O, Prouzet-Mauleon V, Koya J, et al
   MiR-10a and HOXB4 are overexpressed in atypical myeloproliferative neoplasms.
   BMC Cancer. 2018;18:1098.
   PubMed     Text format     Abstract available
   
   

   
   Br J Haematol

7. LANGE AP, Lima AS, Lucena-Araujo AR, Jacomo RH, et al
   The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia.
   Br J Haematol. 2018;180:915-918.
   PubMed     Text format    
   
   
8. DUTTA A, Yan D, Hutchison RE, Mohi G, et al
   STAT3 mutations are not sufficient to induce large granular lymphocytic leukaemia in mice.
   Br J Haematol. 2018;180:911-915.
   PubMed     Text format    
   
   
9. SCHULZ E, Lind K, Renner W, Petersen BS, et al
   The TP53 Pro72Arg SNP in de novo acute myeloid leukaemia - results of two cohort studies involving 215 patients and 3759 controls.
   Br J Haematol. 2018;181:148-151.
   PubMed     Text format    
   
   
10. SOLER AM, Olano N, Mendez Y, Lopes A, et al
    TPMT and NUDT15 genes are both related to mercaptopurine intolerance in acute lymphoblastic leukaemia patients from Uruguay.
    Br J Haematol. 2018;181:252-255.
    PubMed     Text format    
    
    
11. SORA F, Iurlo A, Sica S, Latagliata R, et al
    Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome.
    Br J Haematol. 2018;181:267-270.
    PubMed     Text format    
    
    
12. MOLICA M, Breccia M, Colafigli G, Massaro F, et al
    Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib.
    Br J Haematol. 2018;181:275-278.
    PubMed     Text format    
    
    
13. ARAI H, Nobusawa S, Kawabata-Iwakawa R, Rokudai S, et al
    Myeloid sarcoma arising in malignant phyllodes tumour: clonal relationships revealed by comparative genome-wide analyses.
    Br J Haematol. 2018;181:255-259.
    PubMed     Text format    
    
    
14. LIAO K, Zheng Z, Yang L, Wang L, et al
    Analysis of high-resolution human leucocyte antigen allele polymorphism in 3788 Han Chinese patients with leukaemia.
    Br J Haematol. 2018;181:278-281.
    PubMed     Text format    
    
    
15. MATO AR, Timlin C, Ujjani C, Skarbnik A, et al
    Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study.
    Br J Haematol. 2018;181:259-261.
    PubMed     Text format    
    
    
16. DEMYANETS S, Jaeger E, Pablik E, Greiner G, et al
    The JAK2 blocker TG101209 is a potent inhibitor of clonogenic progenitor cell growth in patients with chronic myeloid leukaemia.
    Br J Haematol. 2018;181:137-139.
    PubMed     Text format    
    
    
17. GIONA F, Saglio G, Santopietro M, Menna G, et al
    Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with high-dose imatinib.
    Br J Haematol. 2018;180:895-898.
    PubMed     Text format    
    
    

    
    Cell

18. BESTER AC, Lee JD, Chavez A, Lee YR, et al
    An Integrated Genome-wide CRISPRa Approach to Functionalize lncRNAs in Drug Resistance.
    Cell. 2018;173:649-664.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Haematol

19. ISHITSUKA K, Yurimoto S, Tsuji Y, Iwabuchi M, et al
    Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma.
    Eur J Haematol. 2019 Feb 10. doi: 10.1111/ejh.13220.
    PubMed     Text format     Abstract available
    
    
20. BALSAT M, Etienne M, Elhamri M, Hayette S, et al
    Successful pregnancies in patients with BCR-ABL-positive leukemias treated with interferon-alpha therapy during the tyrosine kinase inhibitors era.
    Eur J Haematol. 2018;101:774-780.
    PubMed     Text format     Abstract available
    
    
21. WEHMEYER J, Zaiss M, Losem C, Schmitz S, et al
    Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study).
    Eur J Haematol. 2018;101:766-773.
    PubMed     Text format     Abstract available
    
    

    
    Exp Cell Res

22. CHEN P, Zhan W, Wang B, You P, et al
    Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells.
    Exp Cell Res. 2019 Feb 11. pii: S0014-4827(19)30056.
    PubMed     Text format     Abstract available
    
    

    
    Exp Hematol

23. GHORASHIAN S, Amrolia P, Veys P
    Open access? Widening access to chimeric antigen receptor (CAR) therapy for ALL.
    Exp Hematol. 2018;66:5-16.
    PubMed     Text format     Abstract available
    
    
24. SALOME M, Hopcroft L, Keeshan K
    Inverse and correlative relationships between TRIBBLES genes indicate non-redundant functions during normal and malignant hemopoiesis.
    Exp Hematol. 2018;66:63-78.
    PubMed     Text format     Abstract available
    
    

    
    Gene

25. FERRI C, Weich N, Gutierrez L, De Brasi C, et al
    Single nucleotide polymorphism in PTEN-Long gene: A risk factor in chronic myeloid leukemia.
    Gene. 2019;694:71-75.
    PubMed     Text format     Abstract available
    
    

    
    Int J Hematol

26. KIZAKI M, Takahashi N, Iriyama N, Okamoto S, et al
    Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system.
    Int J Hematol. 2019 Feb 14. pii: 10.1007/s12185-019-02613.
    PubMed     Text format     Abstract available
    
    

    
    J Clin Oncol

27. MCNEER JL, Devidas M, Dai Y, Carroll AJ, et al
    Hematopoietic Stem Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group.
    J Clin Oncol. 2019 Feb 11:JCO1800884. doi: 10.1200/JCO.18.00884.
    PubMed     Text format     Abstract available
    
    

    
    J Natl Cancer Inst

28. FIDLER-BENAOUDIA MM, Oeffinger KC
    Childhood leukemia, late effects, and a person-centric model of follow-up.
    J Natl Cancer Inst. 2019 Feb 11. pii: 5313994. doi: 10.1093.
    PubMed     Text format    
    
    
29. SORENSEN GV, Winther JF, de Fine Licht S, Andersen KK, et al
    Long-term risk of hospitalization among five-year survivors of childhood leukemia in the Nordic countries.
    J Natl Cancer Inst. 2019 Feb 11. pii: 5313995. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    Leuk Lymphoma

30. BODDU P, Kantarjian H, Garcia-Manero G, Allison J, et al
    The emerging role of immune checkpoint based approaches in AML and MDS.
    Leuk Lymphoma. 2018;59:790-802.
    PubMed     Text format     Abstract available
    
    

    
    Leukemia

31. MCNEER NA, Philip J, Geiger H, Ries RE, et al
    Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia.
    Leukemia. 2019 Feb 13. pii: 10.1038/s41375-019-0402.
    PubMed     Text format     Abstract available
    
    
32. MROZEK K, Eisfeld AK, Kohlschmidt J, Carroll AJ, et al
    Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically.
    Leukemia. 2019 Feb 8. pii: 10.1038/s41375-019-0390.
    PubMed     Text format     Abstract available
    
    

    
    Oncogene

33. AGUILERA-MONTILLA N, Bailon E, Uceda-Castro R, Ugarte-Berzal E, et al
    MMP-9 affects gene expression in chronic lymphocytic leukemia revealing CD99 as an MMP-9 target and a novel partner in malignant cell migration/arrest.
    Oncogene. 2019 Feb 13. pii: 10.1038/s41388-019-0744.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

34. CASTILLO D, Galvez JM, Herrera LJ, Rojas F, et al
    Leukemia multiclass assessment and classification from Microarray and RNA-seq technologies integration at gene expression level.
    PLoS One. 2019;14:e0212127.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: